VIDO sponsors day on BVD.

S. Acres
1990-03-01
Abstract:The Veterinary Infectious Disease Organization (VIDO) at the University of Saskatchewan sponsored a day on the bovine virus diarrhea mucosal disease (BVD-MD) complex in Saskatoon on October 4, 1989. During the morning, a wet lab was held at VIDO and was attended by eight people from diagnostic laboratories in the four western provinces and two American states. Dr. Helle Bielefeldt Ohmann from VIDO and Dr. Dirk Deregt from the Animal Disease Research Institute, Lethbridge, Alberta demonstrated techniques for culturing BVD virus from blood and other types of samples. They also demonstrated immunoperoxidase staining of the virus in various types of preparations. This will assist the diagnostic laboratories to increase the sensitivity and specificity of the diagnostic techniques which they are using for the virus. It will also assist them to process larger number of samples required for herd screening. During the afternoon, three seminars were presented as the basis for a discussion of case histories brought by the participants. Dr. Dirk Deregt described the molecular biology of BVD virus which is currently classified as a pestivirus but which will likely be reclassified into the flavivirus group within the next year. Dr. Deregt described the various proteins which make up the virus and discussed the potential role of some proteins in the pathogenesis. He also described some of the monoclonal antibodies which have been developed to characterize the proteins and studies which are underway within ADRI to determine if these monoclonals can be used for diagnosis. One protein, designated p80, occurs in cytopathic strains but not in non-cytopathic strains of the virus. However, it is not yet clear whether the presence or absence of this protein explains the difference in cytopathogenicity of the virus in vitro, or differences in pathogenicity in vivo. A second protein, designated gp53 (or gp57 in some laboratories), may be responsible for attachment of the virus to cells since antibody to this protein can neutralize virus-infectivity. Several groups around the world are working to determine whether immunity to gp53 will prevent infection with the virus. The second seminar was presented by Dr. Helle Bielefeldt Ohmann. She described some of her field experiences with the disease in Europe. She also pointed out that some European researchers feel that neutralizing antibody levels are not responsible for protection, but may correlate with it. She also demonstrated that persistently infected animals consistently have large numbers of the virus in many tissues and all secretions, including semen and nasal secretion, and that these animals should not be difficult to detect when appropriate virological techniques are used. Dr. Otto Radostits discussed clinical and epidemiological experiences with BVD-MD in Canada. He acknowledged that the virus does alter immunological function but questioned whether this means that the virus is "immunosuppressive" in field situations. He also questioned the role of BVD virus in outbreaks of feedlot pneumonia. He discussed the rationale for vaccination and reviewed vaccination recommendations for beef and dairy herds.
What problem does this paper attempt to address?